Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer

NCT00232206 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

OTHER

Sponsor class

Stopped study terminated due to slow accrual

Conditions

Non-small-Cell Lung Carcinoma

Interventions

DRUG: Neoadjuvant Therapy with Cisplatin Plus Docetaxel

Sponsor

Providence Health & Services

Collaborators

[object Object]
[object Object]